Display options
Cite
Rajendram R, Lee RW, Potts MJ, et al. Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial. Trials. 2008;9:6doi: 10.1186/1745-6215-9-6.
Rajendram, R., Lee, R. W., Potts, M. J., Rose, G. E., Jain, R., Olver, J. M., Bremner, F., Hurel, S., Cook, A., Gattamaneni, R., Tomlinson, M., Plowman, N., Bunce, C., Hollinghurst, S. P., Kingston, L., Jackson, S., Dick, A. D., Rumsey, N., Morris, O. C., Dayan, C. M., & Uddin, J. M. (2008). Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial. Trials, 96. https://doi.org/10.1186/1745-6215-9-6
Rajendram, Rathie, et al. "Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial." Trials vol. 9 (2008): 6. doi: https://doi.org/10.1186/1745-6215-9-6
Rajendram R, Lee RW, Potts MJ, Rose GE, Jain R, Olver JM, Bremner F, Hurel S, Cook A, Gattamaneni R, Tomlinson M, Plowman N, Bunce C, Hollinghurst SP, Kingston L, Jackson S, Dick AD, Rumsey N, Morris OC, Dayan CM, Uddin JM. Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial. Trials. 2008 Jan 31;9:6. doi: 10.1186/1745-6215-9-6. PMID: 18237441; PMCID: PMC2275219.
Copy Download .nbib Format: NLM
Share it on

Trials. 2008 Jan 31;9:6. doi: 10.1186/1745-6215-9-6.

Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial.

Trials

Rathie Rajendram, Richard W J Lee, Mike J Potts, Geoff E Rose, Rajni Jain, Jane M Olver, Fion Bremner, Steven Hurel, Anne Cook, Rao Gattamaneni, Marjorie Tomlinson, Nicholas Plowman, Catey Bunce, Sandra P Hollinghurst, Laura Kingston, Sue Jackson, Andrew D Dick, Nichola Rumsey, Olivia C Morris, Colin M Dayan, Jimmy M Uddin

Affiliations

  1. Department of Clinical Science at South Bristol, University of Bristol, UK. [email protected]

PMID: 18237441 PMCID: PMC2275219 DOI: 10.1186/1745-6215-9-6

Abstract

BACKGROUND: Medical management of thyroid eye disease remains controversial due to a paucity of high quality evidence on long-term treatment outcomes. Glucocorticoids are known to be effective initially but have significant side-effects with long-term use and recrudescence can occur on cessation. Current evidence is conflicting on the efficacy of radiotherapy and non-steroid systemic immunosuppression, and the majority of previous studies have been retrospective, uncontrolled, small or poorly designed.The Combined Immunosuppression and Radiotherapy in Thyroid Eye Disease (CIRTED) trial was designed to investigate the efficacy of radiotherapy and azathioprine in combination with a standard course of oral prednisolone in patients with active thyroid eye disease.

METHODS/DESIGN: Patients with active thyroid eye disease will be randomised to receive (i) azathioprine or oral placebo and (ii) radiotherapy or sham-radiotherapy in this multi-centre, factorial randomised control trial. The primary outcome is improvement in disease severity (assessed using a composite binary measure) at 12 months and secondary end-points include quality of life scores and health economic measures.

DISCUSSION: The CIRTED trial is the first study to evaluate the role of radiotherapy and azathioprine as part of a long-term, combination immunosuppressive treatment regime for Thyroid Eye Disease. It will provide evidence for the role of radiotherapy and prolonged immunosuppression in the management of this condition, as well as pilot data on their use in combination. We have paid particular attention in the trial design to establishing (a) robust placebo controls and masking protocols which are effective and safe for both radiotherapy and the systemic administration of an antiproliferative drug; (b) constructing effective inclusion and exclusion criteria to select for active disease; and (c) selecting pragmatic outcome measures.

TRIAL REGISTRATION: Current controlled trials ISRCTN22471573.

References

  1. Eur J Clin Invest. 1986 Oct;16(5):415-22 - PubMed
  2. Br J Ophthalmol. 1998 Jul;82(7):773-9 - PubMed
  3. J Clin Endocrinol Metab. 2000 Jan;85(1):102-8 - PubMed
  4. J Clin Endocrinol Metab. 2001 Aug;86(8):3562-7 - PubMed
  5. Rheumatology (Oxford). 2004 Jan;43(1):13-8 - PubMed
  6. Clin Endocrinol (Oxf). 1997 Jul;47(1):9-14 - PubMed
  7. Ophthalmology. 2003 Mar;110(3):450-1; author reply 451 - PubMed
  8. J Endocrinol Invest. 1991 Nov;14(10):853-60 - PubMed
  9. Thyroid. 2002 Mar;12(3):245-50 - PubMed
  10. BMJ. 2004 Aug 14;329(7462):385-90 - PubMed
  11. Ophthalmology. 2003 Mar;110(3):450; author reply 450 - PubMed
  12. Clin Endocrinol (Oxf). 2001 Mar;54(3):391-8 - PubMed
  13. Baillieres Clin Endocrinol Metab. 1997 Oct;11(3):521-36 - PubMed
  14. J Clin Endocrinol Metab. 2005 Sep;90(9):5234-40 - PubMed
  15. Eur J Clin Pharmacol. 2004 Jan;59(11):797-801 - PubMed
  16. Clin Sci. 1945;5(3-4):177-94 - PubMed
  17. Gut. 1993 Aug;34(8):1081-5 - PubMed
  18. Psychol Med. 1998 May;28(3):551-8 - PubMed
  19. N Engl J Med. 1989 Nov 16;321(20):1353-9 - PubMed
  20. Ophthalmology. 2001 Sep;108(9):1523-34 - PubMed
  21. Clin Endocrinol (Oxf). 1987 Jul;27(1):33-42 - PubMed
  22. BMC Med Res Methodol. 2003 Nov 24;3:26 - PubMed
  23. Ophthalmic Plast Reconstr Surg. 2002 May;18(3):175-6 - PubMed
  24. Clin Endocrinol (Oxf). 2001 Sep;55(3):283-303 - PubMed
  25. Rev Gastroenterol Disord. 2003;3 Suppl 1:S30-8 - PubMed
  26. Ophthalmology. 2001 Sep;108(9):1521-2 - PubMed
  27. Endocrinol Metab Clin North Am. 1987 Jun;16(2):391-407 - PubMed
  28. JAMA. 2003 May 21;289(19):2545-53 - PubMed
  29. J Clin Endocrinol Metab. 2004 Dec;89(12):5910-5 - PubMed
  30. Arch Ophthalmol. 2005 Apr;123(4):491-6 - PubMed
  31. Lancet. 2000 Apr 29;355(9214):1505-9 - PubMed
  32. Ophthalmic Plast Reconstr Surg. 2002 May;18(3):170-2 - PubMed
  33. Ophthalmology. 2003 Mar;110(3):449; author reply 449-50 - PubMed
  34. Eur J Endocrinol. 2002 Jun;146(6):751-7 - PubMed
  35. Aust N Z J Med. 1991 Dec;21(6):844-9 - PubMed
  36. Clin Exp Immunol. 1996 Nov;106(2):197-202 - PubMed
  37. Lancet. 1993 Oct 16;342(8877):949-54 - PubMed
  38. Ann Intern Med. 1995 Jul 15;123(2):132-42 - PubMed
  39. Ophthalmology. 2003 Mar;110(3):452-3; author reply 453-4 - PubMed
  40. Br J Ophthalmol. 2002 Jan;86(1):102-4 - PubMed
  41. J Clin Endocrinol Metab. 2004 Jan;89(1):13-4 - PubMed
  42. Ophthalmic Plast Reconstr Surg. 2002 May;18(3):173-4 - PubMed
  43. Eye (Lond). 1997;11 ( Pt 5):717-22 - PubMed
  44. J Endocrinol Invest. 2003 Jan;26(1):5-16 - PubMed
  45. Orbit. 2006 Mar;25(1):27-9 - PubMed
  46. Arch Ophthalmol. 2005 Mar;123(3):356-62 - PubMed
  47. Acta Psychiatr Scand. 1983 Jun;67(6):361-70 - PubMed
  48. Acta Endocrinol (Copenh). 1990 Jan;122(1):8-12 - PubMed
  49. N Engl J Med. 2004 Jun 17;350(25):2591-602 - PubMed
  50. J Clin Endocrinol Metab. 2004 Jan;89(1):15-20 - PubMed
  51. Curr Opin Ophthalmol. 2004 Aug;15(4):293-8 - PubMed
  52. Br J Health Psychol. 2005 May;10(Pt 2):285-98 - PubMed
  53. J Clin Endocrinol Metab. 1983 Jun;56(6):1139-44 - PubMed
  54. Transplantation. 1998 Nov 15;66(9):1186-92 - PubMed
  55. Clin Endocrinol (Oxf). 1993 Apr;38(4):367-72 - PubMed
  56. Ophthalmology. 2003 Mar;110(3):451-2; author reply 452 - PubMed
  57. Clin Endocrinol (Oxf). 1997 Jul;47(1):15 - PubMed
  58. Endocr Rev. 2000 Apr;21(2):168-99 - PubMed

Publication Types